259 related articles for article (PubMed ID: 28612287)
1. Methylation markers differentiate thyroid cancer from benign nodules.
Stephen JK; Chen KM; Merritt J; Chitale D; Divine G; Worsham MJ
J Endocrinol Invest; 2018 Feb; 41(2):163-170. PubMed ID: 28612287
[TBL] [Abstract][Full Text] [Related]
2. Gene expression of thyroid-specific transcription factors may help diagnose thyroid lesions but are not determinants of tumor progression.
Batista FA; Ward LS; Marcello MA; Martins MB; Peres KC; Torricelli C; Bufalo NE; Soares FA; da Silva MJ; Assumpção LV
J Endocrinol Invest; 2016 Apr; 39(4):423-9. PubMed ID: 26370671
[TBL] [Abstract][Full Text] [Related]
3. DNA Methylation-Based Method to Differentiate Malignant from Benign Thyroid Lesions.
Barros-Filho MC; Dos Reis MB; Beltrami CM; de Mello JBH; Marchi FA; Kuasne H; Drigo SA; de Andrade VP; Saieg MA; Pinto CAL; Kowalski LP; Rogatto SR
Thyroid; 2019 Sep; 29(9):1244-1254. PubMed ID: 31328658
[No Abstract] [Full Text] [Related]
4. DNA Methylation Haplotype Block Markers Efficiently Discriminate Follicular Thyroid Carcinoma from Follicular Adenoma.
Zhang H; Zhang Z; Liu X; Duan H; Xiang T; He Q; Su Z; Wu H; Liang Z
J Clin Endocrinol Metab; 2021 Mar; 106(4):1011-1021. PubMed ID: 33394038
[TBL] [Abstract][Full Text] [Related]
5. The diagnostic application of RNA sequencing in patients with thyroid cancer: an analysis of 851 variants and 133 fusions in 524 genes.
Pagan M; Kloos RT; Lin CF; Travers KJ; Matsuzaki H; Tom EY; Kim SY; Wong MG; Stewart AC; Huang J; Walsh PS; Monroe RJ; Kennedy GC
BMC Bioinformatics; 2016 Jan; 17 Suppl 1(Suppl 1):6. PubMed ID: 26818556
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms.
Kebebew E; Peng M; Reiff E; Duh QY; Clark OH; McMillan A
Surgery; 2005 Dec; 138(6):1102-9; discussion 1109-10. PubMed ID: 16360397
[TBL] [Abstract][Full Text] [Related]
7. Role of gene expression profiling in defining indeterminate thyroid nodules in addition to BRAF analysis.
Borrelli N; Ugolini C; Giannini R; Antonelli A; Giordano M; Sensi E; Torregrossa L; Fallahi P; Miccoli P; Basolo F
Cancer Cytopathol; 2016 May; 124(5):340-9. PubMed ID: 26749005
[TBL] [Abstract][Full Text] [Related]
8. Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules.
Finley DJ; Arora N; Zhu B; Gallagher L; Fahey TJ
J Clin Endocrinol Metab; 2004 Jul; 89(7):3214-23. PubMed ID: 15240595
[TBL] [Abstract][Full Text] [Related]
9. Alterations of regulatory factors and DNA methylation pattern in thyroid cancer.
Iancu IV; Botezatu A; Plesa A; Huica I; Fudulu A; Albulescu A; Bostan M; Mihaila M; Grancea C; Manda DA; Dobrescu R; Vladoiu SV; Anton G; Badiu CV
Cancer Biomark; 2020; 28(2):255-268. PubMed ID: 32390600
[TBL] [Abstract][Full Text] [Related]
10. Circulating microRNA124-3p, microRNA9-3p and microRNA196b-5p may be potential signatures for differential diagnosis of thyroid nodules.
Yu S; Liu X; Zhang Y; Li J; Chen S; Zheng H; Reng R; Zhang C; Chen J; Chen L
Oncotarget; 2016 Dec; 7(51):84165-84177. PubMed ID: 27705935
[TBL] [Abstract][Full Text] [Related]
11. IS MEASUREMENT OF CIRCULATING TUMOR DNA OF DIAGNOSTIC USE IN PATIENTS WITH THYROID NODULES?
Lupo M; Guttler R; Geck Z; Tonozzi TR; Kammesheidt A; Braunstein GD
Endocr Pract; 2018 May; 24(5):453-459. PubMed ID: 29498908
[TBL] [Abstract][Full Text] [Related]
12. Expression and significance of IGF-1 and IGF-1R in thyroid nodules.
Liu YJ; Qiang W; Shi J; Lv SQ; Ji MJ; Shi BY
Endocrine; 2013 Aug; 44(1):158-64. PubMed ID: 23288662
[TBL] [Abstract][Full Text] [Related]
13. Genetic markers differentiating follicular thyroid carcinoma from benign lesions.
Freitas BC; Cerutti JM
Mol Cell Endocrinol; 2010 May; 321(1):77-85. PubMed ID: 19932149
[TBL] [Abstract][Full Text] [Related]
14. Molecular Testing for Oncogenic Gene Alterations in Pediatric Thyroid Lesions.
Mostoufi-Moab S; Labourier E; Sullivan L; LiVolsi V; Li Y; Xiao R; Beaudenon-Huibregtse S; Kazahaya K; Adzick NS; Baloch Z; Bauer AJ
Thyroid; 2018 Jan; 28(1):60-67. PubMed ID: 29108474
[TBL] [Abstract][Full Text] [Related]
15. Detection of global hypermethylation in well-differentiated thyroid neoplasms by immunohistochemical (5-methylcytidine) analysis.
Keelawat S; Thorner PS; Shuangshoti S; Bychkov A; Kitkumthorn N; Rattanatanyong P; Boonyayothin W; Poumsuk U; Ruangvejvorachai P; Mutirangura A
J Endocrinol Invest; 2015 Jul; 38(7):725-32. PubMed ID: 25740063
[TBL] [Abstract][Full Text] [Related]
16. Methylation status of TSHr in well-differentiated thyroid cancer by using cytologic material.
Kartal K; Onder S; Kosemehmetoglu K; Kilickap S; Tezel YG; Kaynaroglu V
BMC Cancer; 2015 Oct; 15():824. PubMed ID: 26519197
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
Abd-El Raouf SM; Ibrahim TR
Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
[TBL] [Abstract][Full Text] [Related]
18. Carbonic anhydrase 4 and crystallin α-B immunoreactivity may distinguish benign from malignant thyroid nodules in patients with indeterminate thyroid cytology.
Davidov T; Nagar M; Kierson M; Chekmareva M; Chen C; Lu SE; Lin Y; Chernyavsky V; Potdevin L; Arumugam D; Barnard N; Trooskin S
J Surg Res; 2014 Aug; 190(2):565-74. PubMed ID: 24880201
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive DNA Methylation Profiling Identifies Novel Diagnostic Biomarkers for Thyroid Cancer.
Park JL; Jeon S; Seo EH; Bae DH; Jeong YM; Kim Y; Bae JS; Kim SK; Jung CK; Kim YS
Thyroid; 2020 Feb; 30(2):192-203. PubMed ID: 31797753
[No Abstract] [Full Text] [Related]
20. Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.
Jug RC; Datto MB; Jiang XS
Cancer Cytopathol; 2018 Jul; 126(7):471-480. PubMed ID: 29637728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
